Avacta Group (LSE:AVCT) FCF Margin % : -67.18% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Avacta Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Avacta Group's Free Cash Flow for the six months ended in Dec. 2023 was £-7.63 Mil. Avacta Group's Revenue for the six months ended in Dec. 2023 was £11.36 Mil. Therefore, Avacta Group's FCF Margin % for the quarter that ended in Dec. 2023 was -67.18%.

As of today, Avacta Group's current FCF Yield % is -10.70%.

The historical rank and industry rank for Avacta Group's FCF Margin % or its related term are showing as below:

LSE:AVCT' s FCF Margin % Range Over the Past 10 Years
Min: -741.92 Med: -261.04 Max: -69.4
Current: -69.4

During the past 13 years, the highest FCF Margin % of Avacta Group was -69.40%. The lowest was -741.92%. And the median was -261.04%.

LSE:AVCT's FCF Margin % is ranked better than
58.85% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs LSE:AVCT: -69.40

Avacta Group FCF Margin % Historical Data

The historical data trend for Avacta Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group FCF Margin % Chart

Avacta Group Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-289.21

-574.02

-741.92

-178.09

-69.40

Avacta Group Semi-Annual Data
	Jul13	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jul18	Jan19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-755.93	-182.94	-171.62	-71.53	-67.18

Competitive Comparison of Avacta Group's FCF Margin %

For the Biotechnology subindustry, Avacta Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avacta Group's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Avacta Group's FCF Margin % falls into.

Avacta Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Avacta Group's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-16.134	/	23.247
	=	-69.40 %

Avacta Group's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.63	/	11.358
	=	-67.18 %

Avacta Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Avacta Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avacta Group (LSE:AVCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AVCTF:USA RTQ1:Germany

Address

Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA

Website

https://www.avacta.com

Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines